EyePoint Pharmaceuticals and OcuMension Therapeutics Announced the Approval of New Drug Application for YUTIQ by China’s NMPA for the Treating of Chronic Non-Infectious Uveitis Affecting the Posterior Section of the Eye
On June 21, 2022,- EyePoint Pharmaceuticals, Inc. a pharmaceutical company devoted to develop and commercialize therapeutics to help enhance the lives of patients with grave eye disorders, alonh withOcuMension Therapeutics, a fast-growing ophthalmology fixated pharmaceutical company in China, announced the approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18mg by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for treating chronic non-infectious uveitis that affects the posterior section of the eye.
On June 21, 2022,- EyePoint Pharmaceuticals, Inc. a pharmaceutical company devoted to developing and commercializing therapeutics to help enhance the lives of patients with grave eye disorders, along with OcuMension Therapeutics, fast-growing ophthalmology fixated pharmaceutical company in China, announced the approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18mg by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for treating chronic non-infectious uveitis that affects the posterior section of the eye. YUTIQ is the first drug that has been approved for commercialization in China depending entirely on real-world data, besides being the first drug permitted for commercial use in OcuMension’sgroundbreaking pipeline.
OcuMension launched a study of YUTIQ in September 2020, for the treatment of chronic, non-infectious uveitis affecting the posterior section of the eye at the BoaoLecheng Super Hospital in the Hainan Province of China. Consequently, the CDE recognizedOcuMension’snovel drug application (NDA) for YUTIQ in April 2021, which was filed with the real-world data gathered at BoaoLecheng Super Hospital.
According to the CEO of EyePoint Pharmaceuticals, Nancy Lurker, YUTIQ’s approval in China is an important milestone for OcuMensionand EyePoint’sshared mission of fetching sustained-release drug delivery treatments to patients with incapacitating diseases of the eye. Since YUTIQ’s U.S. approval about three years ago in 2018, EyePoint has been delivering this innovative ocular therapy and providing an upgraded standard of care for patients by supplying around three years of constant control in non-infectious, chronic uveitis affecting the posterior section of the eye.
